Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205606 | 0.88 | PTGDR2 (0.43) | NR3C1PTGDR2MEN1KMT2ATHRA | |
| SCHEMBL883855 | 0.88 | PTGDR2 (0.43) | NR3C1PTGDR2MEN1KMT2A | |
| SCHEMBL2065427 | 0.87 | PTGDR2 (0.52) | NR3C1PTGDR2EPAS1 | |
| SCHEMBL883878 | 0.87 | PTGDR2 (0.44) | NR3C1PTGDR2MEN1KMT2A | |
| SCHEMBL2065489 | 0.85 | PTGDR2 (0.41) | NR3C1PTGDR2MEN1KMT2AEPAS1 | |
| SCHEMBL885395 | 0.85 | THRB (0.41) | NR3C1PTGDR2MEN1KMT2ATHRA | |
| SCHEMBL10121257 | 0.84 | PTGDR2 (0.40) | NR3C1PTGDR2MEN1KMT2A | |
| SCHEMBL2067780 | 0.84 | PTGDR2 (0.41) | NR3C1PTGDR2MEN1KMT2AEPAS1 | |
| SCHEMBL883850 | 0.80 | PTGDR2 (0.48) | NR3C1PTGDR2EPAS1 | |
| SCHEMBL883915 | 0.79 | NR3C1 (0.42) | NR3C1PTGDR2THRATHRBEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1937632-A1 | NOVEL COMPOUNDS | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192163-A1 | Novel Compounds | PAH, PC, DDC | NR3C1 986/4885PTGDR2 1000/4885MEN1 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.